We are happy to announce that Aniling has been selected to participate in the virtual immersion in the Silicon Valley health and entrepreneurship ecosystem (DISRUPTOUR). This great initiative, organized by …
Our close collaborator, Germans Trias i Pujol Research Institute (IGTP), is hiring. IGTP is looking for a highly motivated NGS Technologist. The call for applications will close on October 31th …
Aniling has participated in the “Matchmaking en Diagnóstico in Vitro: Un impulso a la cadena de valor en salud”. Llorenç Coll, CEO at Aniling, had the opportunity for pitching and …
Aniling had a great time in The Investment Readiness Series (Medtech Edition). Thanks Biocat to bring together investors and startups and increase the deal flow of projects ready for investment.
Aniling has attended “The Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology” organized by the Cell Press and the National Cancer Institute (NCI). Sheila Santín has presented the advances of …
Aniling has attended to the International Workshop of Chronic Lymphocytic Leukemia (iwCLL2021), the biennial international meeting committed to advancing the field of CLL. Ester Cuenca has presented the advances of …
We are very proud to announce that Aniling has reached the CE Mark for our first product, GEUS-CLL, a first-in-class IVD medical device to support the diagnosis, prognosis, treatment selection …
Liquid biopsy tests provide access to tumor DNA in a minimally invasive way, offering great potential in oncology applications, including precision medicine, early cancer diagnosis and disease’s follow-up and monitoring. At Aniling, we have developed a new product, GEUS-LB, targeting …
Thanks to the brilliant Aniling teamwork and the invaluable guidance of Ambit BST, we are happy to announce that Aniling has succeeded in the two stages of audits to achieve the ISO 13485:2016. It has been …
